| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | GSK-1904529A | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | avrainvillamide | CTRPv2 | pan-cancer | AAC | 0.0032 | 0.9 |
| mRNA | paclitaxel | UHNBreast | pan-cancer | AAC | 0.024 | 0.9 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | S-Trityl-L-cysteine | GDSC1000 | pan-cancer | AAC | 0.0039 | 0.9 |
| mRNA | PHA-793887 | CTRPv2 | pan-cancer | AAC | 0.0023 | 0.9 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.0027 | 0.9 |
| mRNA | PRL-3 Inhibitor I | CTRPv2 | pan-cancer | AAC | -0.0028 | 0.9 |
| mRNA | IC-87114 | CTRPv2 | pan-cancer | AAC | -0.0026 | 0.9 |